Understanding neuroimmunological disorders is essential for developing new diagnostic and therapeutic strategies. Rodent models have provided valuable insights, but are sometimes equated with their human counterparts. Here, we summarize how novel technologies may enable an improved human-focused view of immune mechanisms. Recent studies have applied these new technologies to the brain parenchyma, its surrounding cerebrospinal fluid, and peripheral immune compartments. Therapeutic interventions have also facilitated translational understanding in a reverse way. However, with improved technology, access to patient samples remains a rate-limiting step in translational research. We anticipate that next-generation neuroimmunology is likely to integrate, in the immediate future, diverse technical tools for optimal diagnosis, prognosis, and treatment of neuroimmunological disorders.
'Mouse Is Not Man and Blood Is Not Brain'Recent research, preferentially from a 'human point-of-view', is integrating novel technologies and enabling a more defined understanding of disease mechanisms in autoimmune diseases of the central nervous system (CNS) (see Glossary). Animal models such as experimental autoimmune encephalomyelitis (EAE) enable the study of 'aspects' of human diseases; however, these models are poorly suited for drug testing or assessing disease etiology (reviewed in [1,2]). Moreover, one of the major challenges in the field constitutes achieving integration of human data obtained using diverse methodologies and from different tissues. Thus, in this review, we discuss a human-and relevant biomaterial-focused view of CNS autoimmunity, centered around the application of emerging technologies.
HighlightsAutoimmune diseases of the nervous system, particularly multiple sclerosis (MS), are only partly mimicked by commonly used animal models such as experimental autoimmune encephalomyelitis (EAE).